Advertisement

Klinischer Einsatz der ACE-Hemmer

  • R. Schmieder
Part of the Aktuelle Therapieprinzipien in Kardiologie und Angiologie book series (THERAPIEPRINZ.)

Zusammenfassung

Die Prävalenz der arteriellen Hypertonie liegt zwischen 15 und 20%. Epidemiologische Untersuchungen konnten zeigen, daß eine direkte Beziehung zwischen der Höhe des Blutdrucks und der kardiovaskulären Morbidität und Mortalität besteht [81,156]. Umgekehrt gilt, daß eine Senkung eines erhöhten Blutdrucks mit einer Reduktion kardiovaskulärer Komplikationen einhergeht. Als eine der ersten klinisch kontrollierten Untersuchungen konnte die Veterans Administration Study nachweisen, daß bei Patienten mit schwerer arterieller Hypertonie eine antihypertensive Therapie zu einer signifikanten Abnahme der kardiovaskulären Mortalität führte [178]. Während in dieser Untersuchung nur Patienten mit einem diastolischen Blutdruck ≥ 115 mmHg behandelt wurden, liegen inzwischen Ergebnisse vieler multizentrischer klinischer Untersuchungen bei insgesamt über 40000 Patienten vor, die eine Reduzierung der hypertonieassoziierter kardiovaskulärer Morbidität und Mortalität bei der milden arteriellen Hypertonie (diastolischer Blutdruck 90–104 mmHg) und bei der mäßigen arteriellen Hypertonie (diastolischer Blutdruck 105–114 mmHg) nachwiesen [42,65,75,114,126,170,178,179].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Aberg H, Frithz G, Morlin C (1981) Comparison of captopril (SQ 142225) with hydrochlorthiazide in the treatment of essential hypertension. Int J Clin Pharmacol Ther Toxicol 19: 368–371PubMedGoogle Scholar
  2. 2.
    Abraham PA, Opsahl JA, Halstenson CE, Keane WF (1988) Efficacy and renal effects of anlapril therapy for hypertensive patients eith chronic renal insuffieciency. Arch Intern med 148: 2358–2362PubMedCrossRefGoogle Scholar
  3. 3.
    Ajagi AA, Campbell BC, Meredith PA, Kaiman AW, Reid JC (1985) The effect of Captopril on the reflex control heart rate: possible mechanisms. Br J Clin Pharmacol 20: 17–25Google Scholar
  4. 4.
    Anderson S, Meyer TW, Rennke HG, Brenner BM (1989) Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 76: 612–619CrossRefGoogle Scholar
  5. 5.
    Andren L, Karlberg B, Öhman P et al. (1982) Captopril and atenolol combined with hydrochlor– thiazide in essential hypertension. Br J Clin Pharmacol 14: 107S–111SPubMedGoogle Scholar
  6. 6.
    August P, Cody RJ, Sealey JE, Laragh JH (1989) Hemodynamic responses to converting enzyme inhibition in patients with renal disease. Am J Hypertens 2: 599–601PubMedGoogle Scholar
  7. 7.
    Bandiani G, Camaiora E, Nicolini MA, Perotta U (1989) Blood pressure control and progression of renal damage in nephrotic patients. In: Friedman EA, Beyer M, DeSanto NG, Giordano C (eds) Prevention of progressive uremia, vol. 1. Field & Wood, New York, pp 121–124Google Scholar
  8. 8.
    Bauer JH, Reams GP, Lai SM (1987) Renal protective effect of strict blood pressure control with enalapril therapy. Arch Intern Med 147: 1397–1400PubMedCrossRefGoogle Scholar
  9. 9.
    Beckman J, Rifkin H (1987) Unilateral modular diabetic glomerulosclerosis (Kimmelstiel– Wielson): report of a case. Metabolism 22: 715–722CrossRefGoogle Scholar
  10. 10.
    Bedogna V, Valvo E, Casagrande P et al. (1990) Effects of ACE–inhibition in normotensive patients with chronic glomerular disease and normal renal function. Kidney Int 38: 101–107PubMedCrossRefGoogle Scholar
  11. 11.
    Bending JJ, Viberti GC, Bilous RW, Keen H (for the KROC Collaborative Study Group) (1985) Eight–month correction of hyperglycemia in insulin–dependent diabetes mellitus is associated with a significant and sustained reduction of urinary albumin excretion rates in patients with micro–albuminuria. Diabetes [Suppl 3] 34: 69–73Google Scholar
  12. 12.
    Bergström J, Avestrand A, Bucht H, Gutierrez A (1985) Progression of chronic renal failure in man is retarded more frequent clinical follow–ups and better blood pressure control. Clin Nephrol 25: 1–6Google Scholar
  13. 13.
    Bigger JT (1987) Why patients with congestive heart failure die: arrhythmias and sudden cardiac death. Circulation [Suppl IV] 75: 28–35Google Scholar
  14. 14.
    Bjöck S, Nyberg G, Mulec H, Granerus G, Herlitz H, Aurell M (1986) Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. BMJ 293: 471–474CrossRefGoogle Scholar
  15. 15.
    Bolzano K, Arringa J, Bernal R et al. (1987) The antihypertensive effect of lisinopril compared to atenolol in patients with mild to moderate hypertension. J Cardiovasc Pharmacol [Suppl 3] 9: S43–S47CrossRefGoogle Scholar
  16. 16.
    Brazy PC, Stead WW, Fitzwilliam JF (1989) Progression of renal insufficiency: role of blood pressure. Kidney Int 35: 670–674PubMedCrossRefGoogle Scholar
  17. 17.
    Brogden RN, Todd PA, Sorkin EM (1988) Captopril An update of its pharmacodynamic and pharmacokinetic propertie, and therapeutic use in hypertension and congestive heart failure. Drugs 36: 540–600PubMedCrossRefGoogle Scholar
  18. 18.
    Brunkhorst R, Wrenger E, Kühn K. Schmidt FW, Koch K (1989) Effekte einer Captopriltherapie auf die Natrium– und Wasserausscheidung bei Patienten mit Leberzirrhose und Aszites. Klin Wochenschr 67: 774–783Google Scholar
  19. 19.
    Cahan DH, Ucci AA (1984) Acute renal failure, interstitial nephritis, and nephrotic syndrome associated with Captopril. Kidney Int 25: 140–164Google Scholar
  20. 20.
    Capewell S, Tavernes D, Hannan WJ, Muir AL (1989) Acute and chronic arterial and venous effects of Captopril in congestive heart failure. BMJ 299: 942–945PubMedCrossRefGoogle Scholar
  21. 21.
    Captopril Multicenter Research Group (1983) A placebo-controlled trial of Captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 2: 755–763CrossRefGoogle Scholar
  22. 22.
    Captopril Research Group of Japan (1985) Clinical effects of low–dose Captopril plus a thiazide diuretic on mild to moderate essential hypertension. A multicenter double-blind comparison with propanolol. J Cardiovasc Pharmacol [Suppl 1] 7: S77–S81Google Scholar
  23. 23.
    Castellano JJ, Hoover RL, Harper RA, Kanovsky MJ (1985) Heparin and- glomerular epithel cell–separated heparin-like species inhibit mesangial cell proliferation. Am J Pathol 120: 427– 435Google Scholar
  24. 24.
    Cleland JGF, Dargie HJ (1988) Arrhythmias, catecholamines and electrolytes. Am J Cardiol 62: 55AS–59AGoogle Scholar
  25. 25.
    Cohn JN, Archibald DG, Ziesche S et al. (1986) Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 314: 1547–1552PubMedCrossRefGoogle Scholar
  26. 26.
    Cohn JN, Johnson G, Ziesche MS et al. (1991) A comparison of enalapril with hydralazine- isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325: 303– 310PubMedCrossRefGoogle Scholar
  27. 27.
    Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon A (1984) Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311: 819–823PubMedCrossRefGoogle Scholar
  28. 28.
    Cooper WD, Doyle G, Donohoe J et al. (1985) Enalapril in the treatment of hypertension associated with impaired renal function. Br J Clin Pharmacol 20: 280–281Google Scholar
  29. 29.
    Coratelli P, Buongiorno E, Giannattasio M, Passavanti G (1988) Antihypertensive efficacy of enalapril maleate on impaired renal function. Kidney Int [Suppl 25] 34: S204–S206Google Scholar
  30. 30.
    Cowley AJ, Wynne RD, Stainer K, Rowley JM (1986) Symptomatic assessment of patients with heart failure: double-blind comparison of increasing dose of diuretics and Captopril in moderate heart failure. Lancet II: 770–774Google Scholar
  31. 31.
    Creager MA, Halperin J, Bernard DB et al. (1981) Acute regional circulatory and renal hemodynamic effects of converting–enzyme inhibition in patients with congestive heart failure. Circulation 64: 483–487PubMedCrossRefGoogle Scholar
  32. 32.
    Creager MA, Massie BM, Faxon DP et al. (1985) Acute and long-term effects of enalapril on the cardiovascular response to exercise and exercise tolerance in patients with congestive heart failure. J Am Coll Cardiol 6: 163–170PubMedCrossRefGoogle Scholar
  33. 33.
    Curtis JR, Bateman FJA (1975) Use of prazosin in management of hypertension in patients with chronic renal failure and in renal transplant recipients. BMJ II: 432–434Google Scholar
  34. 34.
    Dahlöf B, Pennert K, Wansson L (1992) Reversal of left ventricular hypertrophy in hypertensive patients. Am J Hypertens 5: 95–110PubMedGoogle Scholar
  35. 35.
    Daly P, Rouleau JL, Cousineau D, Burgess HJ (1984) Acute effects of Captopril on the coronary circulation of patients with hypertension and angina. Am J Med 76: 111–117PubMedCrossRefGoogle Scholar
  36. 36.
    Danielsen H, Kornerup H J, Olsen P, Posborg V (1983) Arterial hypertension in chronic glomerulonephritis. An analysis of 310 cases. Clin Nephrol 19: 284–287PubMedGoogle Scholar
  37. 37.
    Dannenberg AL, Kannel WB (1987) Remission of hypertension: The natural history of blood pressure treatment in the Framingham Study. JAMA 257: 1477–1483Google Scholar
  38. 38.
    Dargie HJ, Cleland JGF, Leckie BJ, Inglis CG, East BW, Ford I (1987) Relation of arrhythmias and electrolyte abnormalities to survival in patients with severe chronic heart failure. Circulation [Suppl IV] 75: IV98–IV107Google Scholar
  39. 39.
    Day JL, Simpson CN, Metcalfe J, Page RL (1979) Metabolic consequences of atenolol and propanolol in treatment of essential hypertension. BMJ I: 77–80Google Scholar
  40. 40.
    Devine BL, Fife R, Trust PM (1977) Minoxidil for severe hypertension after failure of other hypotensive drugs. BMJ II: 667–669Google Scholar
  41. 41.
    Ertl G, Kochsiek K (1989) Angiotensin-converting-Enzym-Hemmer und ischämische Herzerkrankung. Dtsch Med Wochenschr 14: 556–560CrossRefGoogle Scholar
  42. 42.
    European Working Party (1985) Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet II: 1349–1354Google Scholar
  43. 43.
    Fagard R, Bulpitt C, Lijnev P, Amery A (1982) Response of the systemic and pulmonary circulation to converting-enzyme inhibition ( Captopril) at rest and during exercise in hypertensive patients. Circulation 65: 33–39Google Scholar
  44. 44.
    Ferme I, Djian J, Tcherdakoff P (1990) Comparative study on montherapy with sustained-release diltiazem 300 mg and enalapril 20 mg in mild to moderate arterial hypertension. J Cardiovasc Pharmacol [Suppl 1] 16: S46–S50Google Scholar
  45. 45.
    Fogo A, Yoshida Y, Glick AD, Homma T, Ichikawa I (1988) Serial microguncture analysis of glomerular function in two rat models of glomerular sclerosis. J Clin Invest 82: 322–330PubMedCrossRefGoogle Scholar
  46. 46.
    Franciosa JA, Wilen MM, Ziesche S, Cohn J (1983) Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol 41: 831–836CrossRefGoogle Scholar
  47. 47.
    Francis GS, Benedict C, Johnstone DE et al. (1990) Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. Circulation 82: 1724–1729PubMedCrossRefGoogle Scholar
  48. 48.
    Freis ED (1960) Hemodynamics of hypertension. Physiol Rev 40: 27–54PubMedGoogle Scholar
  49. 49.
    Freis ED (1990) Rationale against the drug treatment of marginal diastolic systemic hypertension. Am J Cardiol 66: 368–371PubMedCrossRefGoogle Scholar
  50. 50.
    Fritzpatrick MA, Rademacher MT, Frampton CM et al. (1990) Renal effects of ACE-inhibition in ovine heart failure: A comparison of intermittent and continuous ACE-inhibition. J Cardiovasc Pharmacol 16: 629–635CrossRefGoogle Scholar
  51. 51.
    Furberg CD, Yusuf S (1988) Effect of drug therapy on survival in chronic congestive heart failure. Am J Cardiol 62: 41A–45APubMedCrossRefGoogle Scholar
  52. 52.
    Gambaro G, Morbiato F, Cicerello E et al. (1985) Captopril in the treatment of hypertension in type I and type II diabetic patients. J Hypertens [Supp II] 3: S149–S151Google Scholar
  53. 53.
    Ganten D, Schelling P, Flügel RM, Fischer H (1975) Effect of angiotensin II and the angiotensin antagonist PI 13 on isorenin and cell growth in 3T3 mouse cells. Int Res Commun 3: 327Google Scholar
  54. 54.
    Garavaglia GE, Messerli FH, Nunez BD, Schmieder R, Fröhlich ED (1988) All angiotensin converting enzyme (ACE) inhibitors are not alike: disparities in the mechanism of the antihypertensive effect. Am J Hypertens 1: 2145–2165Google Scholar
  55. 55.
    Garavaglia GE, Messerli FH, Nunez BD, Schmieder R, Fröhlich ED (1988) Immediate and short-term cardiovascular effects of a new converting enzyme inhibitor (lisinopril) in essential hypertension. Am J Cardiol 62: 912–916PubMedCrossRefGoogle Scholar
  56. 55a.
    Geiger H (1993) Ist die Hyperlipidämie ein Progressionsfaktor der Niereninsuffizienz? Z Kardiol [Suppl 4] 82: 35–38Google Scholar
  57. 57.
    Giles TD, Katz R, Sullivan JM et al. (1989) Short- and long-acting angiotensin-converting enzyme inhibitors: a randomized trial of lisinopril versus Captopril in the treatment of congestive heart failure. JACC 6: 1240–1247Google Scholar
  58. 58.
    Goodwin FJ (1984) A comparative study of enalapril and propanolol in mild to moderate essential hypertension. Symposium on the Management of Congestive Heart Failure and Hypertension, London,abstrC17Google Scholar
  59. 59.
    Guidicelli JF, Berdeaux A, Edonard A, Richer C, Jacolot D (1985) The effect of enalapril on baroreceptor mediated reflex function in normotensive subjects. Br J Clin Pharmacol 20: 211–218Google Scholar
  60. 60.
    Guyatt GH, Sullivan MJJ, Fallen EL et al. (1988) A controlled trial of digoxin in congestive heart failure. Am J Cardiol 61: 371–375PubMedCrossRefGoogle Scholar
  61. 61.
    Hammermeister KE, DeRouen TA, Dodge HT (1979) Variables predictive of survival in patients with coronary disease: selection by univariate and multivariate analyses from the clinical, electrocardiographic, exercise, artériographie and quantitative angiographic evaluations. Circulation 59: 421–430Google Scholar
  62. 62.
    Hannedouche T, Chauveau P, Fehrat A, Albouze G, Jungers P (1989) Effect of moderate protein restriction on the rate of progression of chronic renal failure. Kidney Int [Suppl 27] 36: S91–S95Google Scholar
  63. 63.
    Heeg JE, de Jong PR, Hem GK von der, de Zeeuw D (1987) Reduction of proteinuria by angiotensin converting enzyme inhibition. Kidney Int 32: 78–83Google Scholar
  64. 64.
    Heeg JE, de Jong PE, Hem GK von der, de Zeeuw D (1989) Antiproteinuric effect of the ACE-inhibitor lisinopril (abstr). Kidney Int 35: 227Google Scholar
  65. 65.
    Helgeland A (1980) Treatment of mild hypertension: a five–year controlled drug trial. The Oslo study. Am J Med 69: 725–732PubMedCrossRefGoogle Scholar
  66. 66.
    Helgeland A, Strommen R, Hageland CH, Tretti S (1986) Enalapril, atenolol, and hydrochlor-thiazide in mild to moderate hypertension. Lancet I: 872–875Google Scholar
  67. 67.
    Herlitz H, Edenö C, Mulec C, Westberg C, Aurell M (1984) Captopril treatment of hypertension and renal failure in systemic lupus erythematosus. Nephron 38: 253–256PubMedCrossRefGoogle Scholar
  68. 68.
    Hollenberg NK (1983) Medical therapy of renovascular hypertension: Efficacy and safety of Captopril in 269 patients. Cardiovasc Rev Rep 4: 854–879Google Scholar
  69. 69.
    Hommel E, Mathiesen E, Edsberg B, Bahnsen M, Parving HH (1986) Acute reduction of arterial blood pressure reduces urinary albumin excretion in type I (insulin-dependent) diabetic patients with incipient nephropathy. Diabetologia 29: 211–215PubMedCrossRefGoogle Scholar
  70. 70.
    Hommel E, Parving HH, Mathiesen E, Edsberg B, Nielsen MD, Giese J (1986) Effect of Captopril on kidney function in insulin–dependent diabetic patients with nephropathy. BMJ 293: 467–470PubMedCrossRefGoogle Scholar
  71. 71.
    Hooke D, Walker RG, Walter NM, D’Apice AJ, Whitworth JA, Kincaid-Smith P (1982) Repeated renal failure with use of Captopril in a cystinotic renal allograft recipient. BMJ [Clin Res] 285: 1538–1543CrossRefGoogle Scholar
  72. 72.
    Hoorntje SJ, Weening JJ, Kallenberg CG, Prins EJ, Donker AJ (1979) Serum-sickness-like syndrome with membranous glomerulopathy in the patient on Captopril (letter). Lancet II: 1297–1301Google Scholar
  73. 73.
    Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM (1981) Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. AM J Physiol 241: F85–93PubMedGoogle Scholar
  74. 74.
    Hricik DE, Browning PJ, Kopelman R, Goorno WE, Madias NE, Dzau VJ (1983) Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney. N Engl J Med 308: 373–376PubMedCrossRefGoogle Scholar
  75. 75.
    Hypertension Detection and Follow-up Program Cooperative Group (1979) Five–years finding of the Hypertension Detection and Follow-up Program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 252: 2562–2571Google Scholar
  76. 76.
    Hypertension Detection and Follow-up Program Cooperative Group (1979) Five-years findings of the Hypertension Detection and Follow-up Program. II. Mortality by race, sex and age. JAMA 242: 2572–2577CrossRefGoogle Scholar
  77. 77.
    Ichikawa I, Yoshida Y, Fogo A, Parkerson ML, Klahr S (1988) Effect of heparin on the glomerular structure and function of remnant nephrons. Kidney Int 34: 638–644PubMedCrossRefGoogle Scholar
  78. 78.
    Ikeda T, Näkayama D, Gomi T, Sakurai J, Yamazaki T, Yuhara M (1989) Captopril, an angiotensin I converting-enzyme inhibitor, decreases proteinuria in hypertensive patients with renal diseases. Nephron 52: 72–75PubMedCrossRefGoogle Scholar
  79. 79.
    Jaeschke R, Guyatt GN (1989) Medical therapy for chronic congestive heart failure. Ann Int Med 110: 758–760PubMedGoogle Scholar
  80. 80.
    Jojart GY, Sonkodi S (1984) Does Captopril induce glycosuria? BMJ [Clin Res] 288: 368–372Google Scholar
  81. 81.
    Kannel WB (1976) Some lessons in cardiovascular epidemiology from Framingham. Am J Cardiol 37: 269–282PubMedCrossRefGoogle Scholar
  82. 82.
    Kannel WB, Cupples A, D’Agostino, Stokes J (1988) Hypertension, antihypertensive treatment and sudden coronary death. The Framingham Study. Hypertension [Suppl II] 3: II45–II50Google Scholar
  83. 83.
    Kaplan NM (1983) New aproaches to the therapy of mild hypertension. Am J Cardiol 51: 621–627PubMedCrossRefGoogle Scholar
  84. 84.
    Karlberg BE, Fyhrquist F, Gronhagen–Risha C, Tikkanen I, Ohman KP (1984) Enalapril and lisinopril in renovascular hypertension: antihypertensive and hormonal effects of two new angiotensin-converting enzyme (ACE) inhibitors: a preliminary report. Scand J Urol Nephrol [Suppl] 79: 103–104Google Scholar
  85. 85.
    Kasiske BL, O’Donnell MP, Cowardin W, Keane WF (1990) Lipids and the kidney. Hypertension 15: 443–450PubMedGoogle Scholar
  86. 86.
    Kendall MJ, Lewis H, Griffith M, Barnett A (1988) Drug treatment of the hypertensive diabetic. J Hypertens 1: 249–258Google Scholar
  87. 87.
    Klahr S, Levey AS, Sandberg AM, Williams GW (1989) Major results of the feasibility study of the Modification of Diet in Renal Disease ( MDRD) Study (abstr ). Kidney Int 35: 195Google Scholar
  88. 88.
    Klahr S, Schreiner G, Ichikawa I (1988) The progression of renal disease. N Engl J Med 318: 1657–1666PubMedCrossRefGoogle Scholar
  89. 89.
    Kleber FX (1990) Munich Mild Heart Failure Trial. Frühzeitige Therapie mit Captopril beugt Pumpversagen vor. Dtsch Ärztebl [Beilage 5] 36: 6–10Google Scholar
  90. 90.
    Kobayshi Y, Tateno S, Yoshiyaki H, Shigematsu H (1983) IGA-Nephropathy. Prognostic significance of proteinuria and histological alterations. Nephron 34: 146–153Google Scholar
  91. 91.
    Kobrin I, Pegram BL, Fröhlich ED (1985) Acute pressure increase and intrarenal hemodynamics in conscious WKY and SHR rats. Am J Physiol 249: Hl 114–H1118 0Google Scholar
  92. 92.
    Koren MJ, Savage DD, Casala PN, Laragh JH, Devereux RB (1990) Changes in left ventricular mass predict risk in essential hypertension (abstr). Circulation [Suppl III] 82: 29Google Scholar
  93. 93.
    Kostis JB (1988) Angiotensin converting enzyme inhibitors II. Clinical use. Am Heart J 116: 1591–1605PubMedCrossRefGoogle Scholar
  94. 94.
    Krolewski AS, Canessa M, Warram JH, Laffel LMB, Christlieb AR, Knowler WC, Rand LJ (1988) Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus. N Engl J Med 318: 140–146PubMedCrossRefGoogle Scholar
  95. 95.
    Lai C, Onnis E, Orani E, Pirisi R, Soro A, Cherchi A (1987) Antiischaemic activity of ACE inhibitor enalapril in normotensive patients with stable effort angina (abstr). J Am Coll Cardiol 9: 192Google Scholar
  96. 96.
    Laser NL, Granditir G, Lagginka AW et al. (1984) Effects of antihypertensive therapy on plasma lipids and lipoproteins in the MRFIT. Am J Med 76: 52–66CrossRefGoogle Scholar
  97. 97.
    Leary WP, Reger AJ (1987) Angiotensin II converting enzyme inhibitors and the renal excretion of urate. Cardiovasc Drug Ther 1: 24CrossRefGoogle Scholar
  98. 98.
    Lee DC, Johnson RA, Bingham JB et al. (1982) Heart failure in outpatients. N Engl J Med 306: 699–705PubMedCrossRefGoogle Scholar
  99. 99.
    Lee WH, Packer M (1986) Prognostic importance of serum sodium concentration and its modifica¬tion by converting–enzyme inhibition in patients with severe chronic heart failure. Circulation 73: 257–267PubMedCrossRefGoogle Scholar
  100. 100.
    Lewis EJ (1987) Glomerular abnormalities in patients receiving angiotensin converting enzyme inhibitor therapy. Kidney Int [Suppl] 20: S138–S142Google Scholar
  101. 101.
    Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin converting enzyme intubation in diabetic nephropathy. N Engl J Med 323: 1456–1462CrossRefGoogle Scholar
  102. 102.
    MacMahon SW, Cutter JA, Neaton JD et al. (1986) Relationship of blood pressure to coronary and stroke morbidity and mortality in clinical trials and epidemiological studies. J Hypertens [Suppl 6] 4: 14–17Google Scholar
  103. 103.
    Mamdani BH, Sy Lim V, Makurkar SD, Katz AI, Dunea G (1974); Recovery from prolonged renal failure in patients with accelerated hypertension. N Engl J Med 291: 1343–1344Google Scholar
  104. 104.
    Mann JFE, Ritz E (1988) ACE–Hemmer bei Niereninsuffizienz. Therapiewoche 38: 1883Google Scholar
  105. 105.
    Marre M, Leblanc H, Suarez L, Guyenne T, Menard J, Passa P (1987) Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria. BMJ 294: 1448–1452PubMedCrossRefGoogle Scholar
  106. 106.
    Massie BM, Conway M (1987) Survival of patients with congestive heart failure: past, present, and future prospects. Circulation [Suppl IV] 75: 11–19Google Scholar
  107. 107.
    Mathiesen ER, Hommel E, Giese J, Parving HH (1991) Effect of Captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 303: 81–86PubMedCrossRefGoogle Scholar
  108. 108.
    McAlpine HM, Morton J J, Leckie B, Dargie HJ (1987) Hemodynamic effects of Captopril in acute left ventricular failure complicating myocardial infarction. J Cardiovasc Pharmacol [Suppl 2] 9: S25–S30CrossRefGoogle Scholar
  109. 109.
    McAreavey D, Robertson JIS (1990) Angiotensin converting enzyme inhibitors and moderate hypertension. Drugs 4013: 326–345CrossRefGoogle Scholar
  110. 110.
    McEwan JR, Fuller RW (1989) Angiotensin converting enzyme inhibitors and cough. J Cardiovasc Pharmacol [Suppl 3] 13: S67–S69CrossRefGoogle Scholar
  111. 111.
    McFate Smith W(1985) Epidemiology of congestive heart failure. Am J Cardiol [Suppl A] 55: 3A–8AGoogle Scholar
  112. 112.
    McKee P, Castelli WP, McNamara PM, Kannel WB (1971) The natural history of congestive heart failure: The Framingham Study. N Engl J Med 285: 1441–1446Google Scholar
  113. 113.
    McMurray J, Fraser DM (1986) Captopril, enalapril and blood glucose. Lancet 1: 1035Google Scholar
  114. 114.
    Medical Research Council Working Party (1985) Medical Research Council trial of treatment of mild hypertension: principal results. BMJ 291: 97–104CrossRefGoogle Scholar
  115. 115.
    Meissner MD, Wilson AR, Jessup M (1988) Renal artery stenosis in heart failure. Am J Cardiol 62: 1307–1308PubMedCrossRefGoogle Scholar
  116. 116.
    Melbourne Diabetic Nephropathy Study Group (1991) Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. BMJ 302:210–216Google Scholar
  117. 117.
    Messerli FH, Fröhlich ED, Suarez DH et al. (1987) Borderline hypertension: Relationship between age, hemodynamics and circulating catecholamines. Circulation 64: 760–764CrossRefGoogle Scholar
  118. 118.
    Messerli FH, Ventura HO, Amodeo C (1987) Angiotensin-converting-enzyme inhibitors. In: Messerli FH (ed) The heart and hypertension. Medical Books, New York, pp 407–418Google Scholar
  119. 119.
    Messerli FH, Schmieder R, Grossmann E, Snyder DW (1990) Alcohol abuse: hypertension, left ventricular hypertrophy, ventricular ectopy. 63rd Scientific Session of American Heart Association, Dallas, 1990. Circulation 82: 395Google Scholar
  120. 120.
    Michel JB, Dussante JC, Choudat C et al. (1986) Effects of antihypertensive treatment in one-clip, two kidney hypertension in rats. Kidney Int 29: 1011–1020PubMedCrossRefGoogle Scholar
  121. 121.
    Michel JB, Dussante JC, Choudat C, Nochy D, Corvol P, Menard J (1987) Renal damage induced in the clipped kidney of one-clip, two-kidney hypertensive rats during normalization of blood pressure by converting enzyme inhibition. Kidney Int [Suppl] 20: S168–S172Google Scholar
  122. 122.
    Mimran A, Insua A, Ribstein J, Monnier L, Bringer J, Mirouze J (1988) Contrasting effects of Captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. J Hypertens 6: 919–923PubMedCrossRefGoogle Scholar
  123. 123.
    Mogensen CE (1982) Diabetes mellitus and the kidney. Kidney Int 21: 673–675PubMedCrossRefGoogle Scholar
  124. 124.
    Mogensen CE (1982) Longterm antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ 285: 685PubMedCrossRefGoogle Scholar
  125. 125.
    Morelli E, Loon NR, Myers BD (1989) Effect of converting enzyme inhibitor on diabetic glomerular injury (abstr). Kidney Int 35: 211Google Scholar
  126. 126.
    Morlin C, Baglivo H, Boeijing JK (1987) Comparative trial of lisinopril and nifedipine in mild to severe essential hypertension. J Cardiovasc Pharmacol [Suppl 3] 9: S49–S52Google Scholar
  127. 127.
    Moser M (1986) Treating hypertension. A review of clinical trials. Am J Med [Suppl 6c] 31: 25–32CrossRefGoogle Scholar
  128. 128.
    Mroczek WJ, Davidov M, Gavrilovich L, Finnerty FA Jr (1969) The value of agressive therapy in the hypertensive patient with azotemia. Circulation 40: 893–904Google Scholar
  129. 129.
    Norman J, Badie-Dezfooly B, Nord EP, Kutz I (1987) EGF-induced mitogenesis in proximal tubular cells: potentiation by angiotensin II. Am J Physiol 253: F299–F309Google Scholar
  130. 130.
    O’Donnel MO, Kasiske BL, Katz SA, Schmitz PG, Keane WF (1988) Enalapril (E) reduces glomerular injury in obese zucker (OZ) rats. American Society of Nephrology, San Antonio (abstract addendum 79 )Google Scholar
  131. 130a.
    Packer M, Gheorghiade M, Young JB et al. (1993) Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med 329: 1–7PubMedCrossRefGoogle Scholar
  132. 131.
    Packer M (1983) Vasodilators and inotropic therapy for severe chronic heart failure: passion and scepticism. J Am Coll Cardiol 51: 841–852CrossRefGoogle Scholar
  133. 132.
    Packer M (1989) Identification of risk factors predisposing to the development of functional renal insufficiency during treatment with converting–enzyme inhibitors in chronic heart failure. Cardiology [Suppl 2] 76: 50–55CrossRefGoogle Scholar
  134. 133.
    Packer M, Gheorghiade M, Young JB et al. (1993) Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med 329: 1–7PubMedCrossRefGoogle Scholar
  135. 134.
    Packer M, Lee WH, Yushak M, Medine N (1986) Comparison of Captopril and enalapril in patients with seyere chronic heart failure. N Engl J Med 315: 847–853PubMedCrossRefGoogle Scholar
  136. 135.
    Parving HH, Hommel E, Smidt UM (1988) Protection of kidney function and decrease in albuminuria by Captopril in insulin dependent diabetics with nephropathy. BMJ 297: 1086–1091PubMedCrossRefGoogle Scholar
  137. 135a.
    Pfeffer MA, Braunwald E et al. (1992) Effect of Captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 327: 662–677CrossRefGoogle Scholar
  138. 136.
    Parving HH, Smidt UM, Anderson AR, Svendsen PAA (1983) Early aggressive antihypertension treatment reduces rate of decline in kidney function in diabetic nephropathy Lancet 1: 1175–1177PubMedCrossRefGoogle Scholar
  139. 137.
    Passa P, LeBlanc H, Marre M (1987) Effects of enalapril in insulin-dependent diabetic subjects with mild to moderate uncomplicated hypertension. Diabetes Care 10: 200–204PubMedCrossRefGoogle Scholar
  140. 138.
    Pfeffer MA, Lamas GA, Vaughan DE, Braunwald E (1988) Effect of Captopril on progressive ventricular dilatation after myocardial infarction. N Engl J Med 319: 80–86PubMedCrossRefGoogle Scholar
  141. 139.
    Pfeffer MA, Braunwald E et al. (1992) Effect of Captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 327: 669–677PubMedCrossRefGoogle Scholar
  142. 140.
    Pohl JEF, Thurston H, Swales JD (1974) Hypertension with renal impairment: Influence of intensive therapy. Q J Med 43: 569–581Google Scholar
  143. 141.
    Pool JL, Gennari J, Goldstein E (1987) Controlled multicenter study of the antihypertensive effects of lisinopril, hydrochlorothiazide, and lisinopril plus hydrochlorothiazide in the treatment of 394 patients with mild to moderate essential hypertension. J Cardiovasc Pharmacol 9: 36–42CrossRefGoogle Scholar
  144. 142.
    Powers ER, Chiaramida A, De Maria AN et al. (1987) A double–blind comparison of lisinopril with Captopril in patients with symptomatic congestive heart failure. J Cardiovasc Pharmacol [Suppl 3] 9: S82–S88CrossRefGoogle Scholar
  145. 143.
    Rambausek M, Rhein C, Waldherr R, Goetz R, Heidland A, Ritz E (1989) Hypertension in chronic idiopathic glomerulonephritis: analysis of 311 biopsied patients. Eur J Clin Invest 19: 176–180PubMedCrossRefGoogle Scholar
  146. 144.
    Reams GP, Bauer JH (1988) Effect of lisinopril monotherapy on renal hemodynamics. Am J Kidney Dis 11: 499–507PubMedGoogle Scholar
  147. 145.
    Reams GP, Bauer JH (1986) Effect of enalapril in subjects with hypertension associated with moderate to severe renal dysfunction. Arch Intern Med 146: 2145–2148PubMedCrossRefGoogle Scholar
  148. 146.
    Reisch C, Mann J, Ritz E (1987) Konversionsenzymhemmer in der antihypertensiven Behandlung niereninsuffizienter Patienten. Dtsch Med Wochenschr 112: 1249–1252PubMedCrossRefGoogle Scholar
  149. 147.
    Remme WJ, Cook MP, Bootsma M (1989) Enalaprilat improves coronary flow without effecting systemic hemodynamics. A local tissue effect? Circulation [Suppl II] 80: II558Google Scholar
  150. 148.
    Remuzzi A, Perticucci E, Ruggenenti P, Mosconi L, Limonta M, Remuzzi G (1991) Angiotensin converting enzyme inhibition improves glomerular size selectivity in IgA nephropathy. Kidney Int 39: 1267–1273PubMedCrossRefGoogle Scholar
  151. 149.
    Remuzzi A, Puntorieri S, Battaglia C, Bertani T, Remuzzi G (1990) Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in rats. J Clin Invest 85: 541–543PubMedCrossRefGoogle Scholar
  152. 150.
    Rett K, Lötz M, Wicklmayr M, Fink E, Jauch KW, Günther B, Dietze G (1988) Improved insulin action by ACE inhibition in type II diabetics. Dtsch Med Wochenschr 113: 243–249PubMedCrossRefGoogle Scholar
  153. 151.
    Richardson A, Bayliss J, Scriven A et al. (1987) Double-blind comparison of Captopril alone against furosemide plus amiloride in mild heart failure. Lancet II: 709–711CrossRefGoogle Scholar
  154. 152.
    Riska H, Sovijärvi ARA, Ahonea A, Salorinne Y, Sundberg S, Stenius-Aarmiala B (1990) Effects of Captopril on blood pressure and respiratory function compared to verapamil in patients with hypertension and asthma. J Cardiovasc Pharmacol 15: 57–61PubMedCrossRefGoogle Scholar
  155. 153.
    Rosman JB, Langer K, Brandl M et al. (1989) Protein-restricted diets in chronic renal failure: a four year follow–up shows limited indications. Kidney Int [Suppl 27] 36: 96–102CrossRefGoogle Scholar
  156. 153a.
    Schmieder RE (1994) Reversal of left ventricular hypertrophy analysis of 142 published studies. Am J Hypertens (in press)Google Scholar
  157. 154.
    Ruilope LM, Miranda B, Morales JM, Rodicio JL, Romero JC, Raij L (1989) Converting enzyme inhibition in chronic renal failure. Am J Kidney Dis 8: 120–126Google Scholar
  158. 155.
    Rumboldt Z, Marinkovic M, Drinovic J (1988) Enalapril versus Captopril: a double-blind multi-center comparison in essential hypertension. Int J Clin Pharmacol Res 8: 181–188PubMedGoogle Scholar
  159. 156.
    Rutau G, Kuller LH, Neaton JP, Wentworth DN, McDonald RH, Smith WM (1988) Mortality associated with diastolic hypertension and isolated systolic hypertension among men screened for the Multiple Risk Factor Intervention Trial. Circulation 77: 504–514CrossRefGoogle Scholar
  160. 157.
    Schmieder R (1990) Regression of left ventricular hypertrophy: A therapeutic goal? J Cardiovasc Pharmacol 16 [Suppl 6]: 16–22Google Scholar
  161. 158.
    Schmieder RE (1994) Reversal of left ventricular hypertrophy: Analysis of 412 published studies. Am J Hypertens 7: 25AGoogle Scholar
  162. 159.
    Schmieder R, Garavaglia GE, Schächinger H, Messerli FH (1990) Glomerular hyperfiltration indicates early target organ damage. JAMA 264: 2775–2782PubMedCrossRefGoogle Scholar
  163. 160.
    Schmieder R, Messerli FH, Garavaglia G, Nunez BD (1990): Glomerular hyperfiltration indicates early target organ damage in essential hypertension. JAMA 264: 2775–2780PubMedCrossRefGoogle Scholar
  164. 161.
    Schmieder R, Messerli FH, Garavaglia GE, Nunez BD, MacPhee A A, Re NR (1988) Does the renin- angiotensin-aldosterone system modify cardiac structure and function in essential hypertension? Am J Med [Suppl 3A] 84: 136–139Google Scholar
  165. 162.
    Sharpe N, Murphy J, Smith H, Yarnon S (1988) Treatment of patients with: symptomless left ventricular dysfunction after myocardial infarction. Lancet I: 255–259Google Scholar
  166. 163.
    SOLVD–Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricu¬lar ejection fraction and congestive heart failure. N Engl J Med 325: 293–302CrossRefGoogle Scholar
  167. 163a.
    The Acute Ramipril Efficacy Study Investigators (1993) Effects of ramipril on mortality and morbidity of survivors of acute myocardial with clinical evidence of heart failure. Lancet 342: 821–828Google Scholar
  168. 164.
    SOLVD-Investigators (1992) Effect of enalapril on morbidity and development of heart failure in asymptomatic patients. N Engl J Med 327: 685–691CrossRefGoogle Scholar
  169. 165.
    Steen VD, Costantino JP, Shapiro AP, Mediger TA (1990) Outcome of renal crises in systemic sclerosis: Relation of availability of angiotensin converting enzyme ( ACE) inhibitors. Ann Intern Med 113: 352–357Google Scholar
  170. 166.
    Strongwater SL, Galvanek EG, Stoff JS (1989) Control of hypertension and reversal of renal failure in undifferentiated connective tissue disease by enalapril. Arch Intern Med 149: 582–585PubMedCrossRefGoogle Scholar
  171. 167.
    Taguma Y, Kitamoto Y, Futaki G et al. (1985) Effect of Captopril on heavy proteinuria in azotemic diabetics. N Engl J Med 313: 1617–1620PubMedCrossRefGoogle Scholar
  172. 168.
    Taylor SH, Lee PS, Sharma SK (1988) A comparison of doxazosin and enalapril in the treatment of mild and moderate essential hypertension. Am Heart J 116: 1820–1825PubMedCrossRefGoogle Scholar
  173. 169.
    The Acute Ramipril Efficacy Study Investigators (1993) Effect of Ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342: 821–828Google Scholar
  174. 170.
    The Australian Therapeutic Trial in Mild Hypertension (1980) Report by the Management Committee. Lancet 1: 1261–1267Google Scholar
  175. 171.
    The Captopril-Digoxin Multicenter Group (1988) Comparative effects of therapy with Captopril and digoxin in patients with mild to moderate heart failure. JAMA 259: 539–544CrossRefGoogle Scholar
  176. 172.
    The CONSENSUS Trial Study Group (1987) Effects of Enalapril on mortality in severe congestive heart failure. N Engl J Med 316: 1429–1435CrossRefGoogle Scholar
  177. 173.
    The Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (1988) The 1988 report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure. Arch Intern Med 148: 1023–1038CrossRefGoogle Scholar
  178. 174.
    Thind GS, Johnson A, Bhatnagar D, Herkel TW (1985) A parallel study of enalapril and Captopril and one year of experience with enalapril treatment in moderate-to-severe hypertension. Am Heart J 109: 852–858PubMedCrossRefGoogle Scholar
  179. 175.
    Tschollar W, Beiz GG (1985) Sublingual Captopril in hypertensive crisis. Lancet II: 34–35Google Scholar
  180. 176.
    Valvo E, Bedogna V, Casagrande P et al. (1988) Captopril in patients with type II diabetes and renal insufficiency: systemic and renal hemodynamic alterations. Am J Med 85: 344–348PubMedCrossRefGoogle Scholar
  181. 177.
    Van der Merwe WM, McLigeyo S, Rowe PA, Briggs JD, Anderton J (1991) Benazepril in chronic renal disease: a double–blind controlled study (abstr). Kidney Int 40: 570Google Scholar
  182. 178.
    Veterans Administration Cooperative Study Group on Antihypertensive Agents (1967) Effects of treatment on morbidity in hypertension I. Results in patients with diastolic blood pressures averaging 115 through 129 mmHg. JAMA 202: 1028–1034CrossRefGoogle Scholar
  183. 179.
    Veterans Administration Cooperative Study Group on Antihypertensive Agents (1970) Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg. JAMA 213: 1143–1152CrossRefGoogle Scholar
  184. 180.
    Viberti GG, Keen H, Wizeman HJ (1987) Raised arterial pressure in parents of proteinuric insulin dependent diabetics. BMJ 295: 515–517PubMedCrossRefGoogle Scholar
  185. 181.
    Vidt DG (1984) A controlled multiclinic study to compare the antihypertensive effects of MK-421, hydrochlorthiazide, and MK-421 combined with hydrochlorthiazide in patients with mild to moderate essential hypertension. J Hypertens [Suppl] 2: S81–S88CrossRefGoogle Scholar
  186. 182.
    Vidt DG, Bravo EL, Fouad FM (1982) Captopril. N Engl J Med 306: 214–219CrossRefGoogle Scholar
  187. 182a.
    Werner MG, Schmeder RE (1993) Rationale Therapie der Herzinsuffizienz. Z Kardiol 82 [Suppl 4]: 7–16PubMedGoogle Scholar
  188. 183.
    Walker WG, Neuwirth R, Neaton J, Cutler J (1990) Renal function change in the multiple risk factor intervention trial (abstr). Circulation [Suppl III] 82: 467Google Scholar
  189. 184.
    Walser M (1990) Progession of chronic renal failure in man. Kidney Int 37:. 1195–2210Google Scholar
  190. 185.
    Weidmann P, Uehlinger DE, Gerber A (1985) Antihypertensive treatment and serum lipoproteins. J Hypertens 3: 297–306PubMedCrossRefGoogle Scholar
  191. 186.
    Weinberger MH (1987) Blood pressure and metabolic responses to hydrochlorthiazide, Captopril,Google Scholar
  192. 190.
    Williams GH (1988) Converting enzyme inhibitors in the treatment of hypertension. N Engl J Med 319: 1517–1525PubMedCrossRefGoogle Scholar
  193. 191.
    Williams WR, Schneider KA, Borhani NU, Schneper HW, Slotkoff LM, Ellefson RD (1986) The relationship between diuretics and serum cholesterol in Hypertension Detection and Follow-up Program participants. Am J Prev Med 2: 248–255PubMedGoogle Scholar
  194. 192.
    Witte PU, Walter U (1987) Comparative double-blind study of ramipril and Captopril in mild to moderate essential hypertension. Am J Cardiol 59: 115D–120DPubMedCrossRefGoogle Scholar
  195. 193.
    Wolfson P, Abermethy D, Dipette DJ, Zusman R (1988) Diltiazem and Captopril alone or in combination for treatment of mild to moderate systemic hypertension. Am J Cardiol 62: 103–108CrossRefGoogle Scholar
  196. 194.
    Yoshida Y, Fogo A, Ichikawa I (1989) Glomerular hemodynamic changes vs hypertrophy in experimental glomerular sclerosis. Kidney Int 35: 645–660CrossRefGoogle Scholar
  197. 195.
    Zachariah PK, Bonnet G, Chrysant SF et al. (1987) Evaluation of antihypertensive efficacy of lisinopril compared to metoprolol in moderate to severe hypertension. J Cardiovasc Pharmacol 9: S53–S58PubMedCrossRefGoogle Scholar
  198. 196.
    Zusman RM (1986) Alternatives to traditional antihypertension therapy. Hypertension 8: 837–842PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • R. Schmieder

There are no affiliations available

Personalised recommendations